포트리스 바이오텍FBIO 주가

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?

Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. Read more on FBIO stock here.

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

MIAMI, May 18, 2026 -- Fortress Biotech, Inc. , an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product...

[SCHEDULE 13G/A] SCHEDULE 13G/A

Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst consensus estimate of $(0.22) by 1381.82 percent. This is a 687.5 percent increase over losses of $(0.48) per share

Fortress Biotech: Q1 Earnings Snapshot

BAY HARBOR ISLAND, Fla. — BAY HARBOR ISLAND, Fla. — Fortress Biotech Inc. on Thursday reported net income of $110.4 million in its first quarter. The Bay Harbor Island, Florida-based company...

♻️ 재탕Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher for $205 million ...

[8-K] 중대 사건 — 8-K

[10-Q] 분기 실적 — 10-Q

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million  Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position...

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

SCOTTSDALE, Ariz., May 06, 2026 -- Journey Medical Corporation , a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration...